GlobeNewswire Inc | Sep 24, 2020 04:00PM EDT

September 24, 2020

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 October 6, 2020.

The new data include analyses characterizing real-world patients with heart failure with reduced ejection fraction (HFrEF) representative of patients in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtivmecarbil. Additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), the completed Phase 2 clinical trial which evaluated omecamtivmecarbil in patients with HFrEF, will also be presented.

Title: Characteristics And Outcomes Of A Real-world Population With Heart Failure WithReduced Ejection Fraction Representative Of Clinical Trial PatientsePoster Number 229Date Wednesday, September 30, 2020 Tuesday, October 6, 2020

Title: Progress from Bench to Bedside and Insights Learned - Myosin ActivatorsSession Excellence in Translation Science: Fast Track Discovery to Application (Joint Session with CVCT)Speaker Fady I. Malik, M.D., Ph.D., FACC, FHFA, Executive Vice President of Research & Development, CytokineticsDate Thursday, October 1, 2020Presentation Time 6:00 8:15 PM ET

Title: The Effect Of The Cardiac Myosin Activator, OmecamtivMecarbil, On Right VentricularStructure And Function In Chronic Systolic Heart Failure (COSMIC-HF)Session Jay N. Cohn New Investigator Award: Clinical/Basic Science SessionSpeaker Tor Biering-Srensen, M.D., Ph.D., MPH, Associate Professor, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen; Research Director, Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev & Gentofte HospitalDate Friday, October 2, 2020Presentation Time 7:15 8:15 PM ETePoster Number 003

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtivmecarbil, a novel cardiac muscle activator. Omecamtivmecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide license to develop and commercialize omecamtivmecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA) for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to research, develop and commercialize other novel mechanism skeletal sarcomere activators (excluding FSTAs). Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics has granted Ji Xing Pharmaceuticals Limited an exclusive license to develop and commercialize CK-274 in China and Taiwan, in accordance with Cytokinetics planned global registration programs. Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").Cytokineticsdisclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the GALACTIC-HF clinical trial, including the expected timing of the availability of top-line results; statements relating to the METEORIC-HF clinical trial; the potential benefits ofomecamtivmecarbil, including its ability to represent a novel therapeutic strategy to increase cardiac muscle function and restore cardiac performance;Cytokinetics'and its partners' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits ofCytokinetics'other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production ofCytokinetics'drug candidates that could slow or prevent clinical development or product approval;Cytokinetics'drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limitCytokinetics'or its partners' ability to conduct clinical trials;Cytokineticsmay be unable to obtain or maintain patent or trade secret protection for its intellectual property; the nature of Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities foromecamtivmecarbil; standards of care may change, renderingCytokinetics'drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indicationsCytokinetics'drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales underCytokinetics'collaboration agreements with such partners. For further information regarding these and other risks related toCytokinetics'business, investors should consultCytokinetics'filings with theSecurities and Exchange Commission.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Communications, Investor Relations(415) 290-7757